COX6A1 Antibody Pair

Table 1: Comparative Analysis of COX6A1 Antibodies

Both antibodies detect COX6A1's liver isoform (85 amino acids, theoretical MW 9 kDa) but show slight MW variations due to post-translational modifications or electrophoresis conditions .

Western Blotting

• Proteintech: Validated in EC109 cell lysates with 1:2,000 dilution

• MyBioSource: Demonstrated in NIH3T3 cells at 1:500-2,000 dilution

• Critical for assessing COX6A1 expression changes in:

  • Hepatocellular carcinoma models with altered O-GlcNAcylation

  • Parkinson's disease-linked CHCHD2-T61I mutations

Immunohistochemistry

• Proteintech: Optimized for paraffin-embedded tissues

• MyBioSource: Tested in human testis samples at 1:100 dilution

• Used to map COX6A1 distribution in:

  • Neurological tissues affected by Mohr-Tranebjærg syndrome

  • Cardiac tissues with complex IV assembly defects

Functional Studies

• Key Findings Using These Antibodies:

  1. PLK1-mediated autophagy degrades COX6A1 during gefitinib-induced hepatotoxicity

  2. HIGD2A requirement for COX3 module assembly in complex IV

  3. Altered expression patterns in Alzheimer's disease models showing:

     • 23% reduction in hippocampal COX6A1 mRNA (P < 0.01)

     • Correlation with Aβ plaque burden (r = -0.42, P = 0.003)

Table 2: Protocol Optimization Guidelines

Critical Notes:

• Cross-reactivity confirmed only within stated species

• 20 µL aliquots of Proteintech antibody contain 0.1% BSA stabilizer

• MyBioSource antibody shows cleaner background in muscle tissues

Clinical and Pathological Relevance

• Neurodegenerative Disease Links:

  • 5-bp deletion in COX6A1 causes axonal Charcot-Marie-Tooth disease

  • 38% reduction in COX6A1 protein levels observed in CMT patients

• Viral Pathogenesis:

  • HIV Tat protein inhibits COX activity (EC50 = 0.4 µM)

  • Causes ΔΨm loss within 15 minutes of exposure